{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:09:53Z","timestamp":1781921393977,"version":"3.54.5"},"reference-count":161,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>For ten years, DNA methylation appeared as a major step in the understanding and issues of prostate cancers. Indeed, although classical biochemical parameters are still useful for prostate cancer diagnosis, they have poor sensitivity and are not specific for prostate cancer subtypes. The recent boom in the identification of specific DNA methylation profiles and the rapid development of liquid biopsies have completely modified the care of patients and may greatly influence outcomes in the future. Indeed, DNA methylation modifications could substantially improve the diagnosis by identifying specific prostate subtypes, improve follow-up to monitor residual disease, improve therapeutic efficiency by predicting the response to treatment, and improve the health quality of patients since these epigenetic modifications can easily be detected in non-invasive liquid biopsies.<\/jats:p>","DOI":"10.3390\/biom15091334","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T12:24:25Z","timestamp":1758198265000},"page":"1334","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Years 2015\u20132025 as a Prospective Decade for the Identification of Specific Methylation Biomarkers of Prostate Cancer"],"prefix":"10.3390","volume":"15","author":[{"given":"Zohair","family":"Selmani","sequence":"first","affiliation":[{"name":"Department of Oncobiology, University Hospital of Besan\u00e7on, 3 Boulevard Alexandre Fleming, F-25000 Besan\u00e7on, France"},{"name":"Universit\u00e9 Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, F-25000 Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6302-7823","authenticated-orcid":false,"given":"Paul","family":"Peixoto","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, F-25000 Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0131-9713","authenticated-orcid":false,"given":"Alexis","family":"Overs","sequence":"additional","affiliation":[{"name":"Department of Oncobiology, University Hospital of Besan\u00e7on, 3 Boulevard Alexandre Fleming, F-25000 Besan\u00e7on, France"},{"name":"Universit\u00e9 Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, F-25000 Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4841-7812","authenticated-orcid":false,"given":"Eric","family":"Hervouet","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, F-25000 Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/emboj.2009.405","article-title":"HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy","volume":"29","author":"Lee","year":"2010","journal-title":"EMBO J."},{"key":"ref_3","first-page":"1","article-title":"Downregulation of CAMK2N1 due to DNA Hypermethylation Mediated by DNMT1 that Promotes the Progression of Prostate Cancer","volume":"2023","author":"Peng","year":"2023","journal-title":"J. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1158\/2767-9764.CRC-23-0248","article-title":"FASN Gene Methylation is Associated with Fatty Acid Synthase Expression and Clinical-genomic Features of Prostate Cancer","volume":"4","author":"Dairo","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13148-019-0746-6","article-title":"DNA methylation in repeat negative prostate biopsies as a marker of missed prostate cancer","volume":"11","author":"Fiano","year":"2019","journal-title":"Clin. Epigenet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.21037\/tau-23-405","article-title":"Gene methylation status in focus of advanced prostate cancer diagnostics and improved individual outcomes","volume":"12","author":"Zhang","year":"2023","journal-title":"Transl. Androl. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1158\/1541-7786.MCR-20-0974","article-title":"REX-1 Represses RASSF1a and Activates the MEK\/ERK Pathway to Promote Tumorigenesis in Prostate Cancer","volume":"19","author":"Liu","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"109501","DOI":"10.1016\/j.cellsig.2019.109501","article-title":"piR-31470 epigenetically suppresses the expression of glutathione S-transferase pi 1 in prostate cancer via DNA methylation","volume":"67","author":"Zhang","year":"2020","journal-title":"Cell Signal."},{"key":"ref_9","first-page":"744","article-title":"Identification of aberrantly methylated-differentially expressed genes and gene ontology in prostate cancer","volume":"21","author":"Wang","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"58199","DOI":"10.18632\/oncotarget.16437","article-title":"Promoter DNA methylation analysis reveals a combined diagnosis of CpG-based biomarker for prostate cancer","volume":"8","author":"Tang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Luo, C., He, S., Zhang, H., He, S., Qi, H., and Wei, A. (2022). Clinical and Biological Significance of DNA Methylation-Driven Differentially Expressed Genes in Biochemical Recurrence After Radical Prostatectomy. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.727307"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1186\/s12967-019-2065-2","article-title":"Identification of key DNA methylation-driven genes in prostate adenocarcinoma: An integrative analysis of TCGA methylation data","volume":"17","author":"Xu","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"14895","DOI":"10.1021\/acsomega.9b01613","article-title":"Genome-Wide DNA Methylation Model for the Diagnosis of Prostate Cancer","volume":"4","author":"Nikas","year":"2019","journal-title":"ACS Omega"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12935-019-0753-x","article-title":"Combined analysis and validation for DNA methylation and gene expression profiles associated with prostate cancer","volume":"19","author":"Tong","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13148-023-01609-3","article-title":"Tumor microenvironment deconvolution identifies cell-type-independent aberrant DNA methylation and gene expression in prostate cancer","volume":"16","author":"Reynolds","year":"2024","journal-title":"Clin. Epigenet."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Liu, B., Liu, Y., Pan, X., Li, M., Yang, S., and Li, S.C. (2019). DNA methylation markers for Pan-Cancer prediction by deep learning. Genes, 10.","DOI":"10.3390\/genes10100778"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/1878-0261.13708","article-title":"Simultaneous detection of eight cancer types using a multiplex droplet digital PCR assay","volume":"19","author":"Neefs","year":"2024","journal-title":"Mol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/pros.23093","article-title":"Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue","volume":"75","author":"Geybels","year":"2015","journal-title":"Prostate"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.prnil.2023.01.001","article-title":"DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia","volume":"11","author":"Kim","year":"2023","journal-title":"Prostate Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/4358292","article-title":"GSTP1Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications","volume":"2016","author":"Martignano","year":"2016","journal-title":"Dis. Markers"},{"key":"ref_21","first-page":"228","article-title":"Promoter methylation profile of GSTP1 and RASSF1A in prostate cancerand benign hyperplasia in Vietnamese men. Turk","volume":"46","author":"Vo","year":"2016","journal-title":"J. Med. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/pros.23895","article-title":"A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer","volume":"79","author":"Patel","year":"2019","journal-title":"Prostate"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12967-016-1014-6","article-title":"Methylation pattern analysis in prostate cancer tissue: Identification of biomarkers using an MS-MLPA approach","volume":"14","author":"Gurioli","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13148-019-0771-5","article-title":"Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies","volume":"11","author":"Yang","year":"2019","journal-title":"Clin. Epigenet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-09-3342","article-title":"Identification of Differentially Methylated Genes in Normal Prostate Tissues from African American and Caucasian Men","volume":"16","author":"Wang","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Moses-Fynn, E., Tang, W., Beyene, D., Apprey, V., Copeland, R., Kanaan, Y., Kwabi-Addo, B., and Chuu, C.-P. (2018). Correlating blood-based DNA methylation markers and prostate cancer risk in African-American men. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203322"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/pros.23053","article-title":"Prospective study of DNA methylation at LINE-1 and Alu in peripheral blood and the risk of prostate cancer","volume":"75","author":"Barry","year":"2015","journal-title":"Prostate"},{"key":"ref_28","first-page":"182","article-title":"Diagnostic Value of GSTP1, RASSF1, and RASSF2 Methylation in Serum of Prostate Cancer Patients","volume":"21","author":"Aykanli","year":"2024","journal-title":"Urol. J."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bryzgunova, O., Bondar, A., Ruzankin, P., Laktionov, P., Tarasenko, A., Kurilshikov, A., Epifanov, R., Zaripov, M., Kabilov, M., and Laktionov, P. (2021). Locus-Specific Methylation of GSTP1, RNF219, and KIAA1539 Genes with Single Molecule Resolution in Cell-Free DNA from Healthy Donors and Prostate Tumor Patients: Application in Diagnostics. Cancers, 13.","DOI":"10.3390\/cancers13246234"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/bjc.2015.240","article-title":"Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease","volume":"113","author":"Reis","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Friedemann, M., Jandeck, C., Tautz, L., Gutewort, K., von Rein, L., Sukocheva, O., Fuessel, S., and Menschikowski, M. (2024). Blood-Based DNA Methylation Analysis by Multiplexed OBBPA-ddPCR to Verify Indications for Prostate Biopsies in Suspected Prostate Cancer Patients. Cancers, 16.","DOI":"10.3390\/cancers16071324"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/17501911.2024.2365625","article-title":"Promoter hypermethylation of Y-chromosome gene PRKY as a potential biomarker for the early diagnosis of prostate cancer","volume":"16","author":"Dai","year":"2024","journal-title":"Epigenomics"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wang, Y., Liu, W., Chen, Z., Zang, Y., Xu, L., Dai, Z., Zhou, Y., and Zhu, J. (2024). A noninvasive method for predicting clinically significant prostate cancer using magnetic resonance imaging combined with PRKY promoter methylation level: A machine learning study. BMC Med. Imaging, 24.","DOI":"10.1186\/s12880-024-01236-1"},{"key":"ref_34","first-page":"176","article-title":"Methylation pattern of caveolin-1 in prostate cancer as potential cfDNA biomarker","volume":"23","author":"Pezelj","year":"2023","journal-title":"Biomol. Biomed."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"110330","DOI":"10.1016\/j.isci.2024.110330","article-title":"Prostate cancer detection through unbiased capture of methylated cell-free DNA","volume":"27","author":"Lleshi","year":"2024","journal-title":"iScience"},{"key":"ref_36","first-page":"1183","article-title":"Molecular Diagnostic of Prostate Cancer from Body Fluids Using Methylation-Specific PCR (MS-PCR) Method","volume":"62","author":"Minciu","year":"2016","journal-title":"Clin. Lab."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"The Movember Urine Biomarker Consortium, Zhao, F., Olkhov-Mitsel, E., Kamdar, S., Jeyapala, R., Garcia, J., Hurst, R., Hanna, M.Y., Mills, R., and Tuzova, A.V. (2018). A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer. Clin. Epigenet., 10, 147.","DOI":"10.1186\/s13148-018-0575-z"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13148-018-0564-2","article-title":"Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients","volume":"10","author":"Freitas","year":"2018","journal-title":"Clin. Epigenet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-017-0604-0","article-title":"MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b\/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors","volume":"16","author":"Gomez","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/cam4.486","article-title":"Epigenetically altered miR-193b targets cyclin D1 in prostate cancer","volume":"4","author":"Kaukoniemi","year":"2015","journal-title":"Cancer Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13148-018-0524-x","article-title":"A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA","volume":"10","author":"Brikun","year":"2018","journal-title":"Clin. Epigenet."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Shah, P., Taylor, W.R., Negaard, B.J., Gochanour, B.R., Mahoney, D.W., Then, S.S., Devens, M.E., Foote, P.H., Doering, K.A., and Burger, K.N. (2024). Methylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer. Life, 14.","DOI":"10.3390\/life14081024"},{"key":"ref_43","first-page":"479","article-title":"Epigenetic field alterations in non-tumor prostate tissues detect prostate cancer in urine","volume":"9","author":"Khemees","year":"2021","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"40611","DOI":"10.18632\/oncotarget.6141","article-title":"Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer","volume":"6","author":"Yao","year":"2015","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13148-019-0779-x","article-title":"Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel","volume":"11","author":"Nunes","year":"2019","journal-title":"Clin. Epigenet."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Jarrard, W.E., Schultz, A., Etheridge, T., Damodaran, S., Allen, G.O., Jarrard, D., Yang, B., and Suzuki, H. (2019). Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0218950"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kie\u0142b, P., Kowalczyk, K., Gurwin, A., Nowak, \u0141., Krajewski, W., Sosnowski, R., Szyde\u0142ko, T., and Ma\u0142kiewicz, B. (2023). Novel Histopathological Biomarkers in Prostate Cancer: Implications and Perspectives. Biomedicines, 11.","DOI":"10.3390\/biomedicines11061552"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Fiorentino, V., Martini, M., Dell\u2019aquila, M., Musarra, T., Orticelli, E., Larocca, L.M., Rossi, E., Totaro, A., Pinto, F., and Lenci, N. (2020). Histopathological Ratios to Predict Gleason Score Agreement between Biopsy and Radical Prostatectomy. Diagnostics, 11.","DOI":"10.3390\/diagnostics11010010"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.7150\/jca.28577","article-title":"Downregulation of DACT-2 by Promoter Methylation and its Clinicopathological Significance in Prostate Cancer","volume":"10","author":"Li","year":"2019","journal-title":"J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"706","DOI":"10.7150\/jca.65214","article-title":"Promoter Methylation-Mediated NPTX2 Silencing Promotes Tumor Growth in Human Prostate Cancer","volume":"13","author":"Su","year":"2022","journal-title":"J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"154224","DOI":"10.1016\/j.prp.2022.154224","article-title":"Hypermethylation in the promoter region inhibits AJAP1 expression and activates the JAK\/STAT pathway to promote prostate cancer cell migration and stem cell sphere formation","volume":"241","author":"Chen","year":"2022","journal-title":"Pathol.-Res. Pract."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"153","DOI":"10.21873\/anticanres.17402","article-title":"SLC15A2 Serves as a Novel Prognostic Biomarker and Target for Prostate Cancer","volume":"45","author":"Yin","year":"2024","journal-title":"Anticancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ma, J., Xue, K., Jiang, Y., Wang, X., He, D., and Guo, P. (2024). Down-regulation of SLC14A1 in prostate cancer activates CDK1\/CCNB1 and mTOR pathways and promotes tumor progression. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-66020-1"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Ke, S., Liu, Z., Wang, Q., Zhai, G., Shao, H., Yu, X., and Guo, J. (2022). FAM107A Inactivation Associated with Promoter Methylation Affects Prostate Cancer Progression through the FAK\/PI3K\/AKT Pathway. Cancers, 14.","DOI":"10.3390\/cancers14163915"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/iub.2560","article-title":"Solute carrier family 16 member 5 downregulation and its methylation might serve as a prognostic indicator of prostate cancer","volume":"73","author":"Meng","year":"2021","journal-title":"IUBMB Life"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12672-022-00525-x","article-title":"Downregulation of PGM5 expression correlates with tumor progression and poor prognosis in human prostate cancer","volume":"13","author":"Sun","year":"2022","journal-title":"Discov. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Li, S., Zhu, Y., Ma, C., Qiu, Z., Zhang, X., Kang, Z., Wu, Z., Wang, H., Xu, X., and Zhang, H. (2015). Downregulation of EphA5 by promoter methylation in human prostate cancer. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1025-3"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.3892\/ol.2017.6282","article-title":"Association between protocadherin 8 promoter hypermethylation and the pathological status of prostate cancer","volume":"14","author":"Zhang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/iep.12257","article-title":"Promoter hypermethylation of SOX11 correlates with adverse clinicopathological features of human prostate cancer","volume":"98","author":"Pugongchai","year":"2017","journal-title":"Int. J. Exp. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.prp.2017.10.010","article-title":"Aberrant promoter methylation of the PAQR3 gene is associated with prostate cancer","volume":"214","author":"Lounglaithong","year":"2018","journal-title":"Pathol.-Res. Pract."},{"key":"ref_61","first-page":"659","article-title":"Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer","volume":"39","author":"Liu","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Qin, X.-P., Lu, Q.-J., Yang, C.-H., Wang, J., Chen, J.-F., Liu, K., Chen, X., Zhou, J., Pan, Y.-H., and Li, Y.-H. (2022). CRMP4 CpG Hypermethylation Predicts Upgrading to Gleason Score \u2265 8 in Prostate Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.840950"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/aja.aja_3_17","article-title":"Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients","volume":"20","author":"Gao","year":"2018","journal-title":"Asian J. Androl."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"djw282","DOI":"10.1093\/jnci\/djw282","article-title":"Prospective Study ofCRMP4Promoter Methylation in Prostate Biopsies as a Predictor for Lymph Node Metastases","volume":"109","author":"Gao","year":"2017","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"10030","DOI":"10.18632\/oncotarget.3192","article-title":"Manipulation of prostate cancer metastasis by locus-specific modification of the CRMP4 promoter region using chimeric TALE DNA methyltransferase and demethylase","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e1221555","DOI":"10.1080\/2162402X.2016.1221555","article-title":"Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy","volume":"5","author":"Goltz","year":"2016","journal-title":"OncoImmunology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"57726","DOI":"10.18632\/oncotarget.10639","article-title":"A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: A retrospective cohort study","volume":"7","author":"Lipman","year":"2016","journal-title":"Oncotarget"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Ashour, N., Angulo, J.C., Gonz\u00e1lez-Corpas, A., Orea, M.J., Lobo, M.V.T., Colomer, R., Col\u00e1s, B., Esteller, M., and Ropero, S. (2020). Epigenetic Regulation of Gfi1 in Endocrine-Related Cancers: A Role Regulating Tumor Growth. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134687"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.molonc.2016.02.001","article-title":"Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels","volume":"10","author":"Haldrup","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/15592294.2016.1241931","article-title":"CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients","volume":"11","author":"Meller","year":"2016","journal-title":"Epigenetics"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/ijc.32535","article-title":"Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer","volume":"146","author":"Li","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Wang, Z., Deng, T., Long, X., Lin, X., Wu, S., Wang, H., Ge, R., Zhang, Z., Wu, C.-L., and Taplin, M.-E. (2020). Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229754"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"79943","DOI":"10.18632\/oncotarget.13161","article-title":"PD-L1promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy","volume":"7","author":"Gevensleben","year":"2016","journal-title":"Oncotarget"},{"key":"ref_74","first-page":"e66467","article-title":"Promoter Hypermethylation of the BRCA1 Gene as a Novel Biomarker for Prostate Cancer","volume":"16","author":"Saleem","year":"2024","journal-title":"Cureus"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jmoldx.2016.08.008","article-title":"PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies","volume":"19","author":"Uhl","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e13820","DOI":"10.1097\/MD.0000000000013820","article-title":"PITX2 methylation: A novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer","volume":"98","author":"Jiang","year":"2019","journal-title":"Medicine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"10-4238","DOI":"10.4238\/gmr.15026750","article-title":"Prediction efficiency of PITX2 DNA methylation for prostate cancer survival","volume":"15","author":"Luan","year":"2016","journal-title":"Genet. Mol. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13148-016-0270-x","article-title":"PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy","volume":"8","author":"Holmes","year":"2016","journal-title":"Clin. Epigenet."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Rocha, S.M., Sousa, I., Gomes, I.M., Arinto, P., Costa-Pinheiro, P., Coutinho, E., Santos, C.R., Jer\u00f3nimo, C., Lemos, M.C., and Passarinha, L.A. (2021). Promoter Demethylation Upregulates STEAP1 Gene Expression in Human Prostate Cancer: In Vitro and In Silico Analysis. Life, 11.","DOI":"10.3390\/life11111251"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41388-022-02272-3","article-title":"Epigenetic regulation of EIF4A1 through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling in prostate cancer","volume":"41","author":"Wang","year":"2022","journal-title":"Oncogene"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/15592294.2016.1261786","article-title":"LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality","volume":"12","author":"Fiano","year":"2016","journal-title":"Epigenetics"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.gene.2018.06.104","article-title":"ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer","volume":"675","author":"Zhang","year":"2018","journal-title":"Gene"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Tonmoy, M.I.Q., Fariha, A., Hami, I., Kar, K., Al Reza, H., Bahadur, N.M., and Hossain, S. (2022). Computational epigenetic landscape analysis reveals association of CACNA1G-AS1, F11-AS1, NNT-AS1, and MSC-AS1 lncRNAs in prostate cancer progression through aberrant methylation. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-13381-0"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13148-019-0693-2","article-title":"SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy","volume":"11","author":"Li","year":"2019","journal-title":"Clin. Epigenet."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13148-016-0260-z","article-title":"Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy","volume":"8","author":"Geybels","year":"2016","journal-title":"Clin. Epigenet."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12672-025-01833-8","article-title":"Analysing DNA methylation and transcriptomic signatures to predict prostate cancer recurrence risk","volume":"16","author":"Aldakheel","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1159\/000522634","article-title":"DNA Methylation-Mediated Lowly Expressed AOX1 Promotes Cell Migration and Invasion of Prostate Cancer","volume":"107","author":"Wu","year":"2022","journal-title":"Urol. Int."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e32205","DOI":"10.1097\/MD.0000000000032205","article-title":"Construction of DNA methylation-based nomogram for predicting biochemical-recurrence-free survival in prostate cancer","volume":"101","author":"Zhu","year":"2022","journal-title":"Medicine"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Liao, Y., Wu, M., Jia, Y., Mou, R., and Li, X. (2022). EpCAM as a Novel Biomarker for Survivals in Prostate Cancer Patients. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.843604"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2180585","DOI":"10.1080\/15592294.2023.2180585","article-title":"Comparative and integrative analysis of transcriptomic and epigenomic-wide DNA methylation changes in African American prostate cancer","volume":"18","author":"Creighton","year":"2023","journal-title":"Epigenetics"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"110474","DOI":"10.1016\/j.ygeno.2022.110474","article-title":"Epigenome-wide DNA methylation and transcriptome profiling of localized and locally advanced prostate cancer: Uncovering new molecular markers","volume":"114","author":"Liu","year":"2022","journal-title":"Genomics"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13148-021-01119-0","article-title":"A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer","volume":"13","author":"Ylitalo","year":"2021","journal-title":"Clin. Epigenet."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"FitzGerald, L.M., Jung, C.-H., Wong, E.M., Joo, J.E., Bassett, J.K., Dowty, J.G., Wang, X., Dai, J.Y., Stanford, J.L., and O\u2019callaghan, N. (2024). Detection of differentially methylated CpGs between tumour and adjacent benign cells in diagnostic prostate cancer samples. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-66488-x"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13148-019-0742-x","article-title":"Epigenetic silencing of MEIS2 in prostate cancer recurrence","volume":"11","author":"Haldrup","year":"2019","journal-title":"Clin. Epigenet."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Mundbjerg, K., Chopra, S., Alemozaffar, M., Duymich, C., Lakshminarasimhan, R., Nichols, P.W., Aron, M., Siegmund, K.D., Ukimura, O., and Aron, M. (2017). Identifying aggressive prostate cancer foci using a DNA methylation classifier. Genome Biol., 18.","DOI":"10.1186\/s13059-016-1129-3"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2308920","DOI":"10.1080\/15592294.2024.2308920","article-title":"DNA methylation markers for risk of metastasis in a cohort of men with localized prostate cancer","volume":"19","author":"Habeshian","year":"2024","journal-title":"Epigenetics"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"18837","DOI":"10.1002\/cam4.6507","article-title":"Genome-wide methylation profiling of diagnostic tumor specimens identified DNA methylation markers associated with metastasis among men with untreated localized prostate cancer","volume":"12","author":"Chao","year":"2023","journal-title":"Cancer Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/1078-0432.CCR-16-0549","article-title":"Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer","volume":"23","author":"Zhao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e70122","DOI":"10.1002\/cam4.70122","article-title":"WNT5A is a putative epi-driver of prostate cancer metastasis to the bone","volume":"13","author":"Wilkinson","year":"2024","journal-title":"Cancer Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000446446","article-title":"A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy","volume":"97","author":"Angulo","year":"2016","journal-title":"Urol. Int."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygeno.2016.02.004","article-title":"DNA methylation profiles in African American prostate cancer patients in relation to disease progression","volume":"111","author":"Rubicz","year":"2019","journal-title":"Genomics"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10689-022-00325-w","article-title":"Heritable methylation marks associated with prostate cancer risk","volume":"22","author":"Dowty","year":"2023","journal-title":"Fam. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Bjerre, M.T., Strand, S.H., N\u00f8rgaard, M., Kristensen, H., Rasmussen, A.K., Mortensen, M.M., Freds\u00f8e, J., Mouritzen, P., Ulh\u00f8i, B., and \u00d8rntoft, T. (2019). Aberrant DOCK2, GRASP, HIF3A and PKFP Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051173"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/15592294.2016.1148867","article-title":"Methylation profiling identified novel differentially methylated markers includingOPCMLandFLRT2in prostate cancer","volume":"11","author":"Wu","year":"2016","journal-title":"Epigenetics"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.18632\/oncotarget.14391","article-title":"RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy","volume":"8","author":"Strand","year":"2016","journal-title":"Oncotarget"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1158\/1055-9965.EPI-22-0007","article-title":"Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis","volume":"31","author":"Wang","year":"2022","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Daniunaite, K., Bakavicius, A., Zukauskaite, K., Rauluseviciute, I., Lazutka, J.R., Ulys, A., Jankevicius, F., and Jarmalaite, S. (2021). Promoter Methylation of PRKCB, ADAMTS12, and NAALAD2 Is Specific to Prostate Cancer and Predicts Biochemical Disease Recurrence. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22116091"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/pros.23889","article-title":"TWIST2: A new candidate tumor suppressor in prostate cancer","volume":"79","author":"Zhao","year":"2019","journal-title":"Prostate"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Ruiz-Deya, G., Matta, J., Encarnaci\u00f3n-Medina, J., Ortiz-Sanch\u00e9z, C., Dutil, J., Putney, R., Berglund, A., Dhillon, J., Kim, Y., and Park, J.Y. (2021). Differential DNA Methylation in Prostate Tumors from Puerto Rican Men. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020733"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e1030","DOI":"10.1002\/ctm2.1030","article-title":"Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality","volume":"12","author":"Pidsley","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1200\/JCO.2012.47.1847","article-title":"DNA Methylation Signatures for Prediction of Biochemical Recurrence After Radical Prostatectomy of Clinically Localized Prostate Cancer","volume":"31","author":"Haldrup","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/1878-0261.12183","article-title":"Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies","volume":"12","author":"Haldrup","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/pros.23191","article-title":"Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies","volume":"76","author":"Partin","year":"2016","journal-title":"Prostate"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jmoldx.2019.08.003","article-title":"Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients","volume":"22","author":"Savio","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bju.15618","article-title":"Molecular margin status after radical prostatectomy using glutathione S-transferase P1 (GSTP1) promoter hypermethylation","volume":"130","author":"Witt","year":"2021","journal-title":"BJU Int."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Litovkin, K., Van Eynde, A., Joniau, S., Lerut, E., Laenen, A., Gevaert, T., Gevaert, O., Spahn, M., Kneitz, B., and Gramme, P. (2015). DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0130651"},{"key":"ref_117","first-page":"325.e1","article-title":"Methylation status of various gene loci in localized prostate cancer: Novel biomarkers for diagnostics and biochemical recurrence","volume":"41","author":"Eismann","year":"2023","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_118","first-page":"39.e1","article-title":"An integrative DNA methylation model for improved prognostication of postsurgery recurrence and therapy in prostate cancer patients","volume":"38","author":"Jeyapala","year":"2020","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"71833","DOI":"10.18632\/oncotarget.12377","article-title":"A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors","volume":"7","author":"Ahmad","year":"2016","journal-title":"Oncotarget"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/ijc.30038","article-title":"Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer","volume":"138","author":"Rybicki","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"M\u00f8ller, M., Strand, S.H., Mundbjerg, K., Liang, G., Gill, I., Haldrup, C., Borre, M., H\u00f8yer, S., \u00d8rntoft, T.F., and S\u00f8rensen, K.D. (2017). Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients. Sci. Rep., 7.","DOI":"10.1038\/srep40636"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.12659\/MSM.896763","article-title":"Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy","volume":"21","author":"Lin","year":"2015","journal-title":"Med. Sci. Monit."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.12659\/MSM.904366","article-title":"Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer","volume":"23","author":"Lin","year":"2017","journal-title":"Med. Sci. Monit."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"516","DOI":"10.12659\/MSM.897179","article-title":"Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients","volume":"22","author":"Deng","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Londra, D., Mastoraki, S., Bournakis, E., Zavridou, M., Thanos, A., Rampias, T., and Lianidou, E.S. (2021). USP44 Promoter Methylation in Plasma Cell-Free DNA in Prostate Cancer. Cancers, 13.","DOI":"10.3390\/cancers13184607"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.21037\/apm-20-1496","article-title":"Diagnostic value of DACT-2 methylation in serum of prostate cancer patients","volume":"10","author":"Lan","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/pros.23052","article-title":"DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence","volume":"75","author":"Horning","year":"2015","journal-title":"Prostate"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-021-01445-0","article-title":"Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies","volume":"21","author":"Dillinger","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Zavridou, M., Strati, A., Bournakis, E., Smilkou, S., Tserpeli, V., and Lianidou, E. (2021). Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer. Cancers, 13.","DOI":"10.3390\/cancers13040780"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Friedemann, M., Horn, F., Gutewort, K., Tautz, L., Jandeck, C., Bechmann, N., Sukocheva, O., Wirth, M.P., Fuessel, S., and Menschikowski, M. (2021). Increased Sensitivity of Detection of RASSF1A and GSTP1 DNA Fragments in Serum of Prostate Cancer Patients: Optimisation of Diagnostics Using OBBPA-ddPCR. Cancers, 13.","DOI":"10.3390\/cancers13174459"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Bjerre, M.T., N\u00f8rgaard, M., Larsen, O.H., Jensen, S.\u00d8., Strand, S.H., \u00d8stergren, P., Fode, M., Freds\u00f8e, J., Ulh\u00f8i, B.P., and Mortensen, M.M. (2020). Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential. Cells, 9.","DOI":"10.3390\/cells9061362"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/15592294.2020.1712876","article-title":"Evaluating liquid biopsies for methylomic profiling of prostate cancer","volume":"15","author":"Silva","year":"2020","journal-title":"Epigenetics"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI130887","article-title":"Genome-wide plasma DNA methylation features of metastatic prostate cancer","volume":"130","author":"Wu","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.1038\/s41467-022-34012-2","article-title":"The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors","volume":"13","author":"Chen","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/bjc.2015.7","article-title":"A urine-based methylation signature for risk stratification within low-risk prostate cancer","volume":"112","author":"Karnes","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13148-019-0716-z","article-title":"Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging","volume":"11","author":"Bakavicius","year":"2019","journal-title":"Clin. Epigenet."},{"key":"ref_137","first-page":"1","article-title":"epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer","volume":"3","author":"Tuzova","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40164-019-0137-x","article-title":"An expanded biomarker panel for the detection of prostate cancer from urine DNA","volume":"8","author":"Brikun","year":"2019","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_139","first-page":"6917","article-title":"6-gene promoter methylation assay is potentially applicable for prostate cancer clinical staging based on urine collection following prostatic massage","volume":"18","author":"Nekrasov","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-21-3762","article-title":"Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis","volume":"28","author":"Berchuck","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/2159-8290.CD-23-0754","article-title":"Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation","volume":"14","author":"Franceschini","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Westaby, D., Jim\u00e9nez-Vacas, J.M., Figueiredo, I., Rekowski, J., Pettinger, C., Gurel, B., Lundberg, A., Bogdan, D., Buroni, L., and Neeb, A. (2024). BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity. J. Clin. Investig., 134.","DOI":"10.1172\/JCI179998"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Stevens, C., Hightower, A., Buxbaum, S.G., Falzarano, S.M., and Rhie, S.K. (2023). Genomic, epigenomic, and transcriptomic signatures of prostate cancer between African American and European American patients. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1079037"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/1055-9965.EPI-24-0288","article-title":"Differential DNA Methylation in the Benign and Cancerous Prostate Tissue of African American and European American Men","volume":"34","author":"Chernoff","year":"2025","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/pros.24018","article-title":"Identifying and treating ROBO1-ve \/DOCK1+ve prostate cancer: An aggressive cancer subtype prevalent in African American patients","volume":"80","author":"Ferrari","year":"2020","journal-title":"Prostate"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"8356","DOI":"10.18632\/oncotarget.14198","article-title":"Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians","volume":"8","author":"Shiina","year":"2016","journal-title":"Oncotarget"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.21873\/anticanres.13790","article-title":"Association of Genetic Ancestry with DNA Methylation Changes in Prostate Cancer Disparity","volume":"39","author":"Apprey","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1158\/1535-7163.MCT-21-0581","article-title":"Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer","volume":"21","author":"Farah","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Peter, M.R., Bilenky, M., Davies, A., Isserlin, R., Bader, G.D., Fleshner, N.E., Hirst, M., Zoubeidi, A., and Bapat, B. (2021). Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-85812-3"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s43856-025-00783-0","article-title":"5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies","volume":"5","author":"Li","year":"2025","journal-title":"Commun. Med."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Schagdarsurengin, U., Breiding, V., Loose, M., Wagenlehner, F., and Dansranjav, T. (2022). Interleukin-1 receptor associated kinase 1 (IRAK1) is epigenetically activated in luminal epithelial cells in prostate cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.991368"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41419-024-07133-3","article-title":"Loss of miR-200c-3p promotes resistance to radiation therapy via the DNA repair pathway in prostate cancer","volume":"15","author":"Chang","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e2405997","DOI":"10.1002\/advs.202405997","article-title":"PTBP1 Regulates DNMT3B Alternative Splicing by Interacting with RALY to Enhance the Radioresistance of Prostate Cancer","volume":"11","author":"He","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Zhang, C., Ma, S., Hao, X., Wang, Z., and Sun, Z. (2022). Methylation status of TK1 correlated with immune infiltrates in prostate cancer. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.899384"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"B\u00fcttner, T., Dietrich, D., Zarbl, R., Kl\u00fcmper, N., Ellinger, J., Krausewitz, P., and Ritter, M. (2024). Feasibility of Monitoring Response to Metastatic Prostate Cancer Treatment with a Methylation-Based Circulating Tumor DNA Approach. Cancers, 16.","DOI":"10.3390\/cancers16030482"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/pros.23477","article-title":"Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients","volume":"78","author":"Hendriks","year":"2018","journal-title":"Prostate"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2217\/epi-2020-0173","article-title":"Dynamics of the Cell-Free DNA Methylome of Metastatic Prostate Cancer During Androgen-Targeting Treatment","volume":"12","author":"Peter","year":"2020","journal-title":"Epigenomics"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2217\/epi-2022-0103","article-title":"A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancer","volume":"14","author":"Peter","year":"2022","journal-title":"Epigenomics"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1158\/1078-0432.CCR-18-0101","article-title":"Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients","volume":"24","author":"Groot","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13148-021-01155-w","article-title":"Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer","volume":"13","author":"Silva","year":"2021","journal-title":"Clin. Epigenet."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13148-024-01748-1","article-title":"COL25A1 and METAP1D DNA methylation are promising liquid biopsy epigenetic biomarkers of colorectal cancer using digital PCR","volume":"16","author":"Overs","year":"2024","journal-title":"Clin. Epigenet."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/9\/1334\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:47:49Z","timestamp":1760035669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/9\/1334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":161,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["biom15091334"],"URL":"https:\/\/doi.org\/10.3390\/biom15091334","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]}}}